Jazz’ Sunosi (solriamfetol) Receives NICE Recommendation for the Treatment of Excessive Daytime Sleepiness Caused by Narcolepsy

Shots:

NICE has issued a positive Final Appraisal Document which recommends Sunosi (75/150mg, qd) as an option treatment for adults with EDS caused by narcolepsy with/out cataplexy. The therapy will be available in England and Wales
The recommendation is based on the P-III TONES studies to evaluate Sunosi vs PBO in adults patients with EDS. The results demonstrated a clinical effectiveness and safety profile of solriamfetol in patients with narcolepsy & maintain its effect after 6mos. of treatment
Solriamfetol is dual-acting dopamine and noradrenaline reuptake inhibitor & is designed to improve wakefulness and reduce EDS in adult patients with narcolepsy

Click here to read full press release/ article | Ref: Jazz | Image: Jazz